Bronchial Genomic Classifier May Improve Lung Cancer Detection
the Cancer Therapy Advisor take:
A gene-expression classifier may improve the diagnostic performance of bronchoscopy in detecting pulmonary lesions that are suggestive of lung cancer, according to a recent study published in The New England Journal of Medicine.
Researchers led by Gerard Silvestri, MD, of the Medical University of South Carolina looked at 639 patients who were enrolled in 28 centers as part of the prospective AEGIS-1 and AEGIS-2 trials. Among them, 43 percent had undergone bronchoscopic examinations that were nondiagnostic for lung cancer, leading to invasive procedures after bronchoscopy in 35 percent with benign lesions.
They studied a gene-expression classifier in epithelial cells that was collected from normal-appearing mainstem bronchus in order to assess the probability of lung cnacer.
The researchers found that, in AEGIS-1, the classifier had a sensitivity of 88 percent and a specificity of 47 percent. In AEGIS-2, it had a sensitivity of 89 percent and a specificity of 47 percent.
Combination bronchoscopy and classifier had a sensitivity of 96 percent in AEGIS-1 and 98 percent in AEGIS-2. Among 101 patients who had intermediate pretest probability of cancer, negative predictive value of the classifier was 91 percent in those with nondiagnostic bronchoscopic examination.
“In intermediate-risk patients with a nondiagnostic bronchoscopic examination, a negative classifier score provides support for a more conservative diagnostic approach,” the authors concluded.
Gene-expression classifier may improve the diagnostic performance of bronchoscopy in detecting lung cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection
- Outcomes in Pancreatic Cancer Not Improved by Gemcitabine Plus Erlotinib
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT